何庆烽 - 复旦大学

个人简介

教育经历 2016年8月- 2020年5月，美国内布拉斯加大学医学中心，临床药学，药学博士（Pharm.D.） 2012年9月- 2016年6月，复旦大学药学院，药学（临床药学方向），理学学士（BS）工作经历 2022年11月- 至今，复旦大学药学院，临床药学与药事管理系，青年副研究员 2020年9月- 2022年10月，复旦大学药学院，博士后（临床药理方向，合作导师：相小强博士） 2019年9月- 2020年5月，内布拉斯加州立医院门诊药房，实习药师 2017年1月- 2020年5月，内布拉斯加州立医院住院药房，实习药师

研究领域

临床药物治疗模型引导的精准用药基于模型的肝毒性评价

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Haini Wen#; Qingfeng He#; Xiaoqiang Xiang; Zheng Jiao; Jianguang Yu. Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration. Thrombosis Research. 2022,218:24-34. (IF=10.407) Qingfeng He#; Fengjiao Bu#; Qizhen Wang; Min Li; Jiaying Lin; Zhijia Tang; Wen Yao Mak; Xiaomei Zhuang; Xiao Zhu; Hai-shu Lin; Xiaoqiang Xiang. Examination of the Impact of CYP3A4/5 on Drug–Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach. International Journal of Molecular Sciences. 2022,23(9):4485. (IF=5.923) Yawen Yuan#; Qingfeng He#; Shunguo Zhang; Min Li; Zhijia Tang; Xiao Zhu; Zheng Jiao; Weimin Cai; Xiaoqiang Xiang. Application of Physiologically-based Pharmacokinetic Modeling in Preclinical Studies: A Feasible Strategy to Practice the Principles of 3Rs. Frontiers in Pharmacology. 2022,13:895556. (IF=5.810) Zhipin Jin#; Qingfeng He#; Xiao Zhu; Mingshe Zhu; Yike Wang; Xin-an Wu; Qianzhou Lv; Xiaoqiang Xiang. Application of physiologically based pharmacokinetic modelling for the prediction of drug–drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes. Basic & Clinical Pharmacology & Toxicology. 2022,130(5):592-605. (IF=4.080) Qingfeng He#; Fengjiao Bu#; Hongyan Zhang; Qizhen Wang; Xiaoqiang Xiang. Investigation of the Impact of CYP3A5 Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling. Pharmaceuticals. 2021,14(3):198. (IF=5.863) Min Li#; Qingfeng He#; Li Yao; Xiaofeng Wang; Zhijia Tang; Xiao Zhu; Hai-Shu Lin; Xiaoqiang Xiang. Simultaneous Quantification of Propylthiouracil and Its N-β-d Glucuronide by HPLC-MS/MS: Application to a Metabolic Study. Pharmaceuticals. 2021,14(11):1194. (IF=5.863) Xiwei Ji#; Xiangrui Meng#; Xiao Zhu; Qingfeng He; Yimin Cui. Research and development of Chinese anti-COVID-19 drugs. Acta Pharmaceuticals Sinica B. 2022. (IF=11.413) Xiwei Ji#; Xiao Zhu#; Yun Li; Feng Xue; Isabelle Hui San Kuan; Qingfeng He; Xiangrui Meng; Xiaoqiang Xiang; Yimin Cui; Bo Zheng. Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae. Frontiers in Pharmacology. 13:856792. (IF=5.810) 林嘉崟,金冠钦,何庆烽,相小强. PD-1 / P D -L 1 抑制剂免疫相关不良反应在临床试验中的应对策略[J].中国临床药学杂志,2022,31(4):315-320. 王晓文,何庆烽,相小强,韩冰.生理药代动力学模型预测抑酸药物所致药物相互作用的研究进展[J].药学学报,2021,56(08):2197-2203. 王小凤,何庆烽,李哲,相小强.生理药动学模型应用于治疗性抗体研究进展[J].中国现代应用药学,2021,38(19):2453-2462.